Flossbach Von Storch SE Has $104.49 Million Stock Holdings in Medtronic PLC $MDT

Key Points

• Flossbach Von Storch SE trimmed its Medtronic stake by 14.1%, selling 177,862 shares and now holds 1,087,747 shares valued at about $104.49 million (≈0.08% of the company).
• EVP Harry Skip Kiil sold 52,524 shares at an average $97.71 (≈$5.13 million), cutting his ownership by about 61.6%; insiders now hold roughly 0.26% of Medtronic.
• Medtronic beat quarterly EPS and revenue and set FY2026 guidance of 5.62–5.66 EPS, pays a $0.71 quarterly dividend (3.4% yield), and has a "Moderate Buy" analyst consensus (avg. PT $107.80), though recent product/regulatory wins are tempered by a cybersecurity incident that raises near‑term risk.

Flossbach Von Storch SE trimmed its position in Medtronic PLC (NYSE:MDT - Free Report) by 14.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,087,747 shares of the medical technology company's stock after selling 177,862 shares during the period. Flossbach Von Storch SE owned approximately 0.08% of Medtronic worth $104,489,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Artisan Partners Limited Partnership boosted its stake in Medtronic by 2.6% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company's stock valued at $117,579,000 after purchasing an additional 31,314 shares during the last quarter. SageView Advisory Group LLC raised its stake in shares of Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company's stock worth $2,305,000 after purchasing an additional 15,062 shares during the last quarter. CSM Advisors LLC raised its stake in shares of Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company's stock worth $27,169,000 after purchasing an additional 33,167 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company's stock valued at $13,170,000 after purchasing an additional 54,898 shares in the last quarter. Finally, Applied Finance Capital Management LLC purchased a new position in shares of Medtronic during the third quarter valued at approximately $1,308,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.26% of the company's stock.

Medtronic Stock Performance

Shares of Medtronic stock opened at $82.89 on Tuesday. The business's fifty day simple moving average is $89.44 and its 200 day simple moving average is $95.12. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.93 and a 12 month high of $106.33. The firm has a market capitalization of $106.42 billion, a P/E ratio of 23.09, a price-to-earnings-growth ratio of 2.16 and a beta of 0.75.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.4%. Medtronic's dividend payout ratio is currently 79.11%.

Wall Street Analysts Forecast Growth

MDT has been the subject of several recent research reports. Evercore set a $106.00 price target on Medtronic and gave the stock an "outperform" rating in a report on Thursday, April 9th. CICC Research started coverage on shares of Medtronic in a report on Friday, January 30th. They set an "outperform" rating on the stock. William Blair upgraded shares of Medtronic from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 6th. Mizuho lowered their target price on shares of Medtronic from $125.00 to $120.00 and set an "outperform" rating for the company in a report on Monday, April 13th. Finally, Weiss Ratings lowered shares of Medtronic from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, April 21st. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $107.80.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: EU market access expands for robotics/navigation: Medtronic received CE mark for the Stealth AXiS surgical system, a combined planning/navigation/robotics platform for spine and cranial procedures — a commercialization milestone that accelerates Europe rollout after recent U.S. clearances. Medtronic announces CE Mark for Stealth AXiS™ surgical system
• Positive Sentiment: Regulatory and clinical progress for cardiac devices: Medtronic won FDA Breakthrough Device designation for its Sphere-9 catheter for ventricular tachycardia and reported clinical milestones tied to Affera — events that can de-risk future approvals and drive adoption in a high-value segment. Medtronic wins FDA breakthrough nod for Sphere-9 catheter, reports new clinical milestones for Affera
• Positive Sentiment: Product launch expands EMR/DBS footprint: Medtronic launched its Adaptive Deep Brain Stimulation (aDBS) system in India — a commercial expansion that supports revenue diversification in neuromodulation markets. Medtronic Launches Adaptive Deep Brain Stimulation System for Parkinson's Patients in India
• Positive Sentiment: New electrophysiology data at HRS: Medtronic presented PFA and other cardiac device data at HRS 2026, keeping it competitive with Boston Scientific and Abbott in a fast-evolving ablation market. These data can influence adoption and reimbursement momentum. 4 studies to know from HRS 2026
• Neutral Sentiment: Analyst/commentary pieces: Coverage such as Seeking Alpha and Kalkine discuss low expectations and potential upside — useful for sentiment context but not immediate catalysts. Medtronic: Expectations Are Low And That's The Opportunity
• Negative Sentiment: Cybersecurity incident creates investor concern: Medtronic disclosed unauthorized access to portions of its IT systems. Management says patient safety, manufacturing and distribution were not affected and no material financial impact is expected, but the breach increases near-term risk perception around data security and regulatory scrutiny. This is the primary near-term headwind pressuring the stock. Medtronic says cyberattack on IT network has not disrupted operations

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.